Condition
Recurrent Peripheral Primitive Neuroectodermal Tumor
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 8 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
8 shownSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialNCT04320888 · 2021-05-03
ACTIVE_NOT_RECRUITINGTipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialNCT04284774 · 2020-10-13
ACTIVE_NOT_RECRUITINGIvosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)NCT04195555 · 2020-07-20
ACTIVE_NOT_RECRUITINGUlixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)NCT03698994 · 2018-11-14
ACTIVE_NOT_RECRUITINGPalbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)NCT03526250 · 2018-08-13
COMPLETEDSamotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)NCT03213678 · 2017-11-28
COMPLETEDTazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)NCT03213665 · 2017-11-13
COMPLETEDTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)NCT03155620 · 2017-07-31
ACTIVE_NOT_RECRUITINGCommon interventions
Computed TomographyPROCEDURE3Magnetic Resonance ImagingPROCEDURE3X-Ray ImagingPROCEDURE3Biospecimen CollectionPROCEDURE2IvosidenibDRUG2Laboratory Biomarker AnalysisOTHER2PalbociclibDRUG2Pharmacological StudyOTHER2Positron Emission TomographyPROCEDURE2Radionuclide ImagingPROCEDURE2SamotolisibDRUG2SelpercatinibDRUG2TazemetostatDRUG2TipifarnibDRUG2UlixertinibDRUG2Biopsy ProcedurePROCEDURE1Bone Marrow Aspiration and BiopsyPROCEDURE1Bone ScanPROCEDURE1EnsartinibDRUG1ErdafitinibDRUG1FDG-Positron Emission TomographyPROCEDURE1Larotrectinib SulfateDRUG1Mutation Carrier ScreeningPROCEDURE1OlaparibDRUG1Pharmacokinetic StudyOTHER1
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING5
COMPLETED3
Phase mix
PHASE28
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.